QI
LGND icon

Quotient Investors’s Ligand Pharmaceuticals LGND Stock Holding History

Quotient Investors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,488
Closed -$285K – 192
2016
Q4 		$285K Hold
4,488
– – 0.18% 143
2016
Q3 		$286K Hold
4,488
– – 0.18% 152
2016
Q2 		$334K Sell
4,488
-642
-13% -$47.6K 0.16% 164
2016
Q1 		$343K Hold
5,130
– – 0.13% 164
2015
Q4 		$347K Buy
+5,130
New +$317K 0.13% 164

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Quotient Investors's LGND Position: Q1 2017 in Review

Quotient Investors sold out of Ligand Pharmaceuticals (LGND) in Q1 2017, closing a stake of 4,488 shares — an estimated $285K sold.

Quotient Investors first reported a position in LGND in Q4 2015 and held it in 5 quarters. The position peaked at $347K in Q4 2015. 256 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

  • Quotient Investors reported no remaining Ligand Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Quotient Investors sold 4,488 Ligand Pharmaceuticals shares in Q1 2017, an estimated $285K.
  • Quotient Investors first reported a position in Ligand Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Quotient Investors's Ligand Pharmaceuticals position peaked at $347K in Q4 2015.
  • 256 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on Quotient Investors's 13F filing for Q1 2017, filed 19 Apr 2017.